Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Alexandra O SokolovaCatherine H MarshallRebeca LozanoRoman GulatiElisa M LedetNavonil De SarkarPetros GrivasCelestia S HiganoBruce MontgomeryPeter S NelsonDavid OlmosVadim SokolovMichael Thomas SchweizerTodd A YezefskiEvan Y YuChanning J PallerA Oliver SartorElena CastroEmmanuel S AntonarakisHeather H ChengPublished in: The Prostate (2021)
Conventional therapies can be effective in gATM carriers and should be considered before PARPi, which shows limited efficacy in this group. Men with gATM mutations warrant prioritization for novel treatment strategies.